Elsevier

Metabolism

Volume 103, Supplement, February 2020, 153865
Metabolism

Review
Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting

https://doi.org/10.1016/j.metabol.2019.01.006Get rights and content

Highlights

  • Fibroblast Growth Factor 23 (FGF23) is synthesized mainly by osteocytes.

  • FGF23 is a phosphaturic factor that inhibits 1-25 (OH)2 vitamin D and PTH.

  • FGF23 has off-target effects on cardiovascular, immune and central nervous systems.

  • FGF23 is up-regulated in X-linked hypophosphatemia.

Abstract

Phosphate is a cornerstone of several physiological pathways including skeletal development, bone mineralization, membrane composition, nucleotide structure, maintenance of plasma pH, and cellular signaling. The kidneys have a key role in phosphate homeostasis with three hormones having important functions in renal phosphate handling or intestinal absorption: parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and 1–25-dihydroxyvitamin D (1,25(OH)2D). FGF23 is mainly synthesized by osteocytes; it is a direct phosphaturic factor that also inhibits 1,25(OH)2D and PTH. In addition to crucial effects on phosphate and calcium metabolism, FGF23 also has ‘off-target’ effects notably on the cardiovascular, immune and central nervous systems. Genetic diseases may affect the FGF23 pathway, resulting in either increased FGF23 levels leading to hypophosphatemia (such as in X-linked hypophosphatemia) or defective secretion/action of intact FGF23 inducing hyperphosphatemia (such as in familial tumoral calcinosis). The aim of this review is to provide an overview of FGF23 physiology and pathophysiology in X-linked hypophosphatemia, with a focus on FGF23-associated genetic diseases.

Introduction

Phosphate is a key element for several physiological pathways such as skeletal development, bone mineralization, membrane composition, nucleotide structure, maintenance of plasma pH, and cellular signaling [1]. Phosphate is mainly stored in bone, but the kidneys have a key role in phosphate homeostasis with two hormones playing important roles in renal phosphate handling: parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23). Both hormones have hypophosphatemic effects by decreasing tubular phosphate reabsorption, with opposite effects on the regulation of 1,25-dihydroxyvitamin D (1,25(OH)2D). A third main regulator of phosphate metabolism is 1,25(OH)2D which increases phosphate intestinal absorption and inhibits PTH synthesis. An overview of phosphate physiology, with intestinal absorption, renal excretion, and bone metabolism is provided in Fig. 1 [2].

In adults, hypophosphatemia is defined as phosphatemia below 2.5 mg/dL (0.8 mmol/L), while a level below 1 mg/dL (0.3 mmol/L) is considered severe hypophosphatemia [2]. In children, hypophosphatemia is defined based on the age-related normal range [3]. Children with hypophosphatemia from defects of tubular reabsorption of phosphate (e.g., X-linked hypophosphatemia, or proximal tubulopathy such as the De Toni Debre Fanconi syndrome or Dent disease) experience growth retardation, bone deformities and rickets [4]. In the early 2000s, overexpression of FGF23 was initially described in pediatric patients with autosomal dominant X-linked hypophosphatemia XLH [5], and it was also rapidly associated with tumor-induced osteomalacia (TIO) in adults [6], highlighting the key role of FGF23 and its regulators in phosphate physiology.

The aim of this review is to provide an up-to-date overview of FGF23 physiology and pathophysiology in XLH, with a focus on FGF23-associated genetic diseases.

Section snippets

FGF23 Physiology

FGF23 is a 251 amino-acid protein (molecular weight = 30 kDa) with a 24 amino-acid signal peptide in the N-terminal portion; its chromosome location is 12p13 in humans. It belongs to the FGF family, in the sub-group of the ‘endocrine FGFs’ with FGF19 and FGF21 [7]. Although it shares a highly conserved sequence with all the FGFs, it has a unique C-terminal structure as well as a specific three-dimensional configuration (i.e., disulfide bond and β sheet), both accounting for its systemic action [

FGF23-Associated Diseases in Humans

In humans, both FGF23 and Klotho expression can be modified in genetic or acquired diseases. Four groups can be distinguished: diseases with a primary excess in intact FGF23 levels (e.g., genetic X-linked hypophosphatemia and non-genetic tumor-induced osteomalacia); diseases with a primary deficiency in intact FGF23 levels or inefficient FGF23 (e.g., hyperphosphatemic tumoral calcinosis); diseases with a secondary excess in FGF23 concentration (e.g., chronic kidney disease, CKD), and diseases

Animal Models of FGF23 Deficiency and Excess

FGF23 knock-out mice have decreased longevity, growth retardation, skin atrophy, decreased bone density and ectopic as well as vascular calcifications [50]. In addition, they exhibit hyperphosphatemia, hypercalcemia and elevated serum 1,25(OH)2D [50]. These mice also tend to be more sensitive to insulin and are therefore at increased risk of hypoglycemia. In these animals, correcting serum phosphate levels with low phosphate diet without modifying serum calcium or 1,25(OH)2D levels, improves

Experimental Studies in Animals and in Humans

XLH is a dominant disorder caused by mutations in PHEX located on X-chromosome Xp22.1 [53]. PHEX encodes a cell-surface-bound protein cleavage enzyme and is predominantly expressed in osteoblasts, osteocytes, odontoblasts, muscles, teeth, lungs and ovaries [54]. The pathogenesis of XLH is yet not fully understood. The majority of XLH patients as well as Hyp mice, an orthologous animal model of XLH, have elevated FGF23 levels [55]. Excess FGF23 results in renal phosphate wasting and consequent

Conclusion

The management of patients with XLH remained purely symptomatic until recently, using mainly phosphate supplementation, active vitamin D analogs and native vitamin D [4]. After the demonstration of its efficacy in adults and in children [64], burosumab (a FGF23 antibody) was approved by the European Medicines Agency for children with XLH in 2018. This opens a completely new therapeutic paradigm for these patients, and the development of such a targeted therapy is the direct consequence of the

Contributors

JB wrote the first draft of the manuscript; CB and DP reviewed it. All the authors approved the last version of the manuscript.

Acknowledgements

This article is published as part of a supplement supported by Kyowa Kirin Pharma.

Declaration of Competing Interest

The authors declare no conflict of interest.

Funding information

Not relevant for this review.

References (65)

  • L. Ardeshirpour et al.

    Evaluation of bone and mineral disorders

    Pediatr Endocrinol Rev

    (2007)
  • A. Linglart

    Therapeutic management of hypophosphatemic rickets from infancy to adulthood

    Endocr Connect

    (2014)
  • ADHR Consortium

    Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23

    Nat Genet

    (2000)
  • T. Shimada

    Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia

    Proc Natl Acad Sci U S A

    (2001)
  • T. Yamashita

    Structural and biochemical properties of fibroblast growth factor 23

    Ther Apher Dial

    (2005)
  • S. Fukumoto

    Physiological regulation and disorders of phosphate metabolism—pivotal role of fibroblast growth factor 23

    Intern Med

    (2008)
  • F.M. Hannan et al.

    The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases

    Nat Rev Endocrinol

    (2018)
  • Y. Yamazaki

    Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23

    J Bone Miner Res Off J Am Soc Bone Miner Res

    (2008)
  • I.Z. Ben-Dov

    The parathyroid is a target organ for FGF23 in rats

    J Clin Invest

    (2007)
  • O. Andrukhova

    FGF23 promotes renal calcium reabsorption through the TRPV5 channel

    EMBO J

    (2014)
  • E.G. Farrow et al.

    Initial FGF23-mediated signaling occurs in the distal convoluted tubule

    J Am Soc Nephrol

    (2009)
  • M.C. Hu

    Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule

    FASEB J Off Publ Fed Am Soc Exp Biol

    (2010)
  • Q. Chang et al.

    The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel

    Science

    (2005)
  • C. Faul

    FGF23 induces left ventricular hypertrophy

    J Clin Invest

    (2011)
  • H. Olauson

    Parathyroid-specific deletion of klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion

    PLoS Genet

    (2013)
  • J. Bacchetta

    Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes

    J Bone Miner Res Off J Am Soc Bone Miner Res

    (2013)
  • M. Chonchol et al.

    Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study

    J Am Soc Nephrol

    (2016)
  • O. Andrukhova

    FGF23 regulates renal sodium handling and blood pressure

    EMBO Mol Med

    (2014)
  • N. Hensel

    Fibroblast growth factor 23 signaling in hippocampal cells: impact on neuronal morphology and synaptic density

    J Neurochem

    (2016)
  • J. Gardner et al.

    Changes in plasma FGF23 in growth hormone deficient children during rhGH therapy

    J Pediatr Endocrinol Metab

    (2011)
  • B. Spoto et al.

    Circulating adiponectin modifies the FGF23 response to vitamin D receptor activation: a post hoc analysis of a double-blind, randomized clinical trial

    Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc

    (2018)
  • E.A. Imel et al.

    Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans

    J Clin Endocrinol Metab

    (2011)
  • Cited by (59)

    • Vitamin D in dentoalveolar and oral health

      2023, Feldman and Pike's Vitamin D: Volume One: Biochemistry, Physiology and Diagnostics
    • A complex case of renal phosphate wasting…

      2021, Nephrologie et Therapeutique
    View all citing articles on Scopus

    Authors contributions: JB wrote the first draft of the manuscript; CB and DP reviewed it. All the authors approved the last version of the manuscript.

    View full text